장마감
로그인 회원가입
AVLN
AVLN
Avalyn Pharma Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$27.62
-0.33 ▼ -1.18%
🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)
$27.62
+0.00 +0.00%

아발린 파마(AVLN) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$1.2B
스몰캡
P/E
-
배당수익률
없음
52주 위치
38%
저점 +14% · 고점 -17%
애널리스트
적극 매수
C+
Fundamental health
vs. Biotechnology· based on 2 axes
수익성
데이터 부족
성장
Top 64%
밸류에이션
데이터 부족
재무 안정
Top 35%
Index RUTP/E -EPS (ttm) -Insider Own 37.94%Shs Outstand 44.3MPerf Week -3.53%
Market Cap 1.22BForward P/E -EPS next Y 14.18%Insider Trans 9%Shs Float 27.5MPerf Month -4.69%
Enterprise Value 1.49BPEG -EPS next Q -0.74Inst Own 5.7%Short Float 7.96%Perf Quarter -
Income -P/S -EPS this Y 28.45%Inst Trans 81.22%Short Ratio 4.41Perf Half Y -
Sales -P/B -EPS next 5Y 9.19%ROA -Short Interest 2.19MPerf YTD 6.23%
Book/sh -5.96P/C 9.94EPS past 3/5Y -ROE -52W High -17.11% ($33.32)Perf Year -
Cash/sh 2.78P/FCF -Sales past 3/5Y -ROIC -52W Low 14.37% ($24.15)Perf 3Y -
Dividend Est. -EV/EBITDA -EPS Y/Y TTM -Gross Margin -Volatility(W/M) 6.04% 8.14%Perf 5Y -
Dividend TTM -EV/Sales -Sales Y/Y TTM -Oper. Margin -ATR (14) 2.28Perf 10Y -
Dividend Ex-Date -Quick Ratio 10.8EPS Q/Q -Profit Margin -RSI (14) 45.85Recom 1
Dividend Gr. 3/5Y -Current Ratio 10.8Sales Q/Q -SMA20 -3.93% ($28.75)Beta -Target Price $59
Payout -Debt/Eq 0.15Earnings 2026/6/3SMA50 -3.76% ($28.7)Rel Volume 0.39Prev Close $27.95
Employees 50LT Debt/Eq 0.15EPS/Sales Surpr. -265.25% -SMA200 -3.83% ($28.72)Avg Volume(3M) 0.50MPrice $27.62
IPO 2026/4/30Option/Short No/YesTrades 2807Volume 193,549Change -1.18%

📊 Avalyn Pharma Inc (AVLN) Investment Analysis

What kind of company is Avalyn Pharma Inc?

아발린 파마(AVLN) 성장주
Healthcare · Biotechnology
Healthcare Stocks

Avalyn Pharma (AVLN) is a clinical-stage biotech company developing inhaled anti-fibrotic therapies targeting rare respiratory diseases, including pulmonary fibrosis. Its strategy involves reformulating existing oral drugs into inhaled forms to deliver the medication directly to the lungs, thereby reducing side effects from systemic exposure and improving tolerability. Founded in 2011, the company is headquartered in the United States.

Learn more about Avalyn Pharma Inc →
Market Cap
$1.2B
Approx. KRW 1.7 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank2498
Employees50people
IPO2026/04/30
Current Price$27.62 ≈ 37,839원
📌 RUT · NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 6월 3일 (수) · 장 시작 전 EPS -265.3%

Is it profitable?

Financial health solid
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.15
✓ Healthy debt
My positionMid-range
Low range Average High range
Biotechnology Median 0.05
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
10.80
✓ 우수
My positionTop 25%
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
10.80
✓ 우수
My positionTop 25%
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$59.00
현재가 대비 +113.6%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
내년 EPS 예상 성장률
+14.2%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+9.2%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility
Frequently misses analyst estimates
0
예상 상회
0
예상 부합
1
예상 하회
0%
상회 비율
-2578.5%
평균 서프라이즈
2026.06.03
하회
실적 $-21.83 · 예상 $-0.81 -2578.5%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+28.4%
양호
My positionMid-range
Low range Average High range
성장주 소형주 Median 16.2% · Top 31%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+14.2%
평균
My positionMid-range
Low range Average High range
성장주 소형주 Median 17.5% · Bottom 41%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+9.2%
매우 부진
My positionBottom 5%
Low range Average High range
성장주 소형주 Median 18.9% · Bottom tier
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Returns by period
Current position within 52-week range
Low (-14.4%p) High (-17.1%p)
Current price is 14.4% above the 52-week low and 17.1% below the 52-week high
Recent risk (last 60 trading days)
Max drawdown
-22.1%
Annualized volatility
71.8%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 60-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $27.62 below the midline ($28.75). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

Current diagnosis · 2026-07-27
Death cross — bearish reversal signal

MACD(-0.271) crossed below Signal(-0.248). Trend reversal possible; read as a sell entry point.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 45.9 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 49.0.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Valuation data is insufficient

Key metrics such as PER and PBR are unavailable, so valuation is omitted.

Who owns it?

Ownership flow is positive
Insider modest net buying +9.0% · Institutional net buying +81.2% · Short interest moderate 8.0% · Short interest up +3.9pp over last 40d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
+9.0%
Insiders net buying
🏦 Institutions (funds & investors)
+81.2%
Institutions large net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 5.7%
Retail-led
Healthcare 소형주 Median 65.6%
🧑‍💼 Insiders 37.9%
Founder/management large holders (strong skin-in-the-game)
Healthcare 소형주 Median 17.6%
👤 Retail investors (estimated) 56.4%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
8.0%
Moderate
Healthcare 소형주 Median 11.2%
Past 40 days 📈 +3.9%p increase
Short interest days to cover
4.4 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 44.3M주
Float (tradable shares) 27.5M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 40 days.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
AVLN AVLN This Stock
$1.2B- - - - -1.2%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 아발린 파마(AVLN)?

아발린 파마(AVLN) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of AVLN?

The market cap of AVLN is approximately $1.2B, ranking 2,498 within its sector.

What is the 52-week high and low for AVLN?

AVLN has recorded a 52-week high of $33.32 and a low of $24.15.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.